147 related articles for article (PubMed ID: 11405248)
1. Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides.
Hollenberg MD; Saifeddine M
Can J Physiol Pharmacol; 2001 May; 79(5):439-42. PubMed ID: 11405248
[TBL] [Abstract][Full Text] [Related]
2. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist.
Ma L; Hollenberg MD; Wallace JL
Br J Pharmacol; 2001 Oct; 134(4):701-4. PubMed ID: 11606309
[TBL] [Abstract][Full Text] [Related]
3. Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand.
Moschonas IC; Kellici TF; Mavromoustakos T; Stathopoulos P; Tsikaris V; Magafa V; Tzakos AG; Tselepis AD
Platelets; 2017 Dec; 28(8):812-821. PubMed ID: 28267389
[TBL] [Abstract][Full Text] [Related]
4. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
5. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for activation and biased signaling at the thrombin-activated GPCR proteinase activated receptor-4 (PAR4).
Thibeault PE; LeSarge JC; Arends D; Fernandes M; Chidiac P; Stathopulos PB; Luyt LG; Ramachandran R
J Biol Chem; 2020 Feb; 295(8):2520-2540. PubMed ID: 31892516
[TBL] [Abstract][Full Text] [Related]
7. Proteinase-activated receptor 4 (PAR4): action of PAR4-activating peptides in vascular and gastric tissue and lack of cross-reactivity with PAR1 and PAR2.
Hollenberg MD; Saifeddine M; Al-Ani B; Gui Y
Can J Physiol Pharmacol; 1999 Jun; 77(6):458-64. PubMed ID: 10537233
[TBL] [Abstract][Full Text] [Related]
8. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function.
Faruqi TR; Weiss EJ; Shapiro MJ; Huang W; Coughlin SR
J Biol Chem; 2000 Jun; 275(26):19728-34. PubMed ID: 10779527
[TBL] [Abstract][Full Text] [Related]
9. [Role of adenosine diphosphate in the course of thrombin signal transmission].
Han Y; Lu XX; Wang ZY; Dai L; Shen WH; Wu DP; Ruan CG
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(46):3299-301. PubMed ID: 17313817
[TBL] [Abstract][Full Text] [Related]
10. Dual endothelium-dependent vascular activities of proteinase-activated receptor-2-activating peptides: evidence for receptor heterogeneity.
Roy SS; Saifeddine M; Loutzenhiser R; Triggle CR; Hollenberg MD
Br J Pharmacol; 1998 Apr; 123(7):1434-40. PubMed ID: 9579740
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the distinct mechanism of agonist-induced canine platelet activation.
Chaudhary PK; Kim S
J Vet Sci; 2019 Jan; 20(1):10-15. PubMed ID: 30541187
[TBL] [Abstract][Full Text] [Related]
12. A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity.
Han X; Knauss EA; Fuente M; Li W; Conlon RA; LePage DF; Jiang W; Renna SA; McKenzie SE; Nieman MT
J Thromb Haemost; 2024 Jun; 22(6):1715-1726. PubMed ID: 38508397
[TBL] [Abstract][Full Text] [Related]
13. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
Holinstat M; Voss B; Bilodeau ML; McLaughlin JN; Cleator J; Hamm HE
J Biol Chem; 2006 Sep; 281(36):26665-74. PubMed ID: 16837456
[TBL] [Abstract][Full Text] [Related]
14. Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides.
Hollenberg MD; Saifeddine M; al-Ani B; Kawabata A
Can J Physiol Pharmacol; 1997 Jul; 75(7):832-41. PubMed ID: 9315351
[TBL] [Abstract][Full Text] [Related]
15. Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo.
Hollenberg MD; Saifeddine M; Sandhu S; Houle S; Vergnolle N
Br J Pharmacol; 2004 Oct; 143(4):443-54. PubMed ID: 15451771
[TBL] [Abstract][Full Text] [Related]
16. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
Covic L; Gresser AL; Kuliopulos A
Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of proteinase-activated receptor agonists on human platelets.
Chung AW; Jurasz P; Hollenberg MD; Radomski MW
Br J Pharmacol; 2002 Mar; 135(5):1123-32. PubMed ID: 11877318
[TBL] [Abstract][Full Text] [Related]
19. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.
Vretenbrant K; Ramström S; Bjerke M; Lindahl TL
Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets.
Cumashi A; Ansuini H; Celli N; De Blasi A; O'Brien PJ; Brass LF; Molino M
Thromb Haemost; 2001 Mar; 85(3):533-8. PubMed ID: 11307827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
